Federal Register / Vol. 72, No. 13 / Monday, January 22, 2007 / Notices 2703 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The purpose of this 

meeting is to evaluate requests for 

preclinical development resources for 

potential new therapeutics for type 1 

diabetes. The outcome of the evaluation 

will be a decision whether NIDDK 

should support the request and make 

available contract resources for 

development of the potential 

therapeutic to improve the treatment or 

prevent the development of type 1 

diabetes and its complications. The 

research proposals and the discussions 

could disclose confidential trade secrets 

or commercial property such as 

patentable material, and personal 

information concerning individuals 

associated with the proposed research 

projects, the disclosure of which would 

constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Type 1 Diabetes—

Rapid Access to Intervention Development 

Special Emphasis Panel; National Institute of 

Diabetes and Digestive and Kidney Diseases. 

Date: January 23, 2007. 

Time: 3 p.m. to 4 p.m. 

Agenda: To evaluate requests for 

preclinical development resources for 

potential new therapeutics for type 1 diabetes 

and its complications. 

Place: 6707 Democracy Boulevard, 

Bethesda, MD 20892, (Telephone Conference 

Call). 

Contact Person: Dr. Myrlene Staten, Senior 

Advisor, Diabetes Transplation Research, 

Division of Diabetes, Endocrinology and 

Metabolic Diseases, NIDDK, NIH, 6707 

Democracy Boulevard, Bethesda, MD 20892–

5460, 301 402–7886. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.277, Diabetes, 

Endocrinology and Metabolic Research; 

93.848, Digestive Diseases and Nutrition 

Research; 98.849, Kidney Diseases, urology 

and Hematology Research, National Institutes 

of Health, HHS) 

This notice is being published less 

than 15 days prior to the meeting due 

to the timing limitations imposed by the 

review and funding cycle. 

Dated: January 11, 2007. 

Anna Snouffer, 

Acting Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 07–235 Filed 1–19–07; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Biomedical 

Imaging and Bioengineering; Notice of 

Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Biomedical Imaging and Bioengineering 

Special Emphasis Panel, ZEB1 OSR–D M1 

Training Grants Review. 

Date: February 27, 2007. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Double Tree Hotel Rockville, 1750 

Rockville Pike, Rockville, MD 20852. 

Contact Person: John Hayes, Scientific 

Review Administrator, 6707 Democracy 

Blvd., Suite 959, Democracy Two, Bethesda, 

MD 20892, (301) 451–3398, 

hayesj@mail.nih.gov. 

Dated: January 12, 2007. 

David Clary, 

Acting Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 07–238 Filed 1–19–07; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Arthritis and 

Musculoskeletal and Skin Diseases; 

Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of a meeting of the 

Board of Scientific Counselors, NIAMS. 

The meeting will be closed to the 

public as indicated below in accordance 

with the provisions set forth in section 

552b(c)(6), Title 5 U.S.C., as amended 

for the review, discussion, and 

evaluation of individual intramural 

programs and projects conducted by the 

National Institute of Arthritis and 

Musculoskeletal and Skin Diseases, 

including consideration of personnel 

qualifications and performance, and the 

competence of individual investigators, 

the disclosure of which would 

constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Board of Scientific 

Counselors, NIAMS. 

Date: February 8–9, 2007. 

Time: 1 p.m. to 1:30 p.m. 

Agenda: To review and evaluate personal 

qualifications and performance, and 

competence of individual investigators. 

Place: National Institutes of Health, 

Building 31, 31 Center Drive, Conference 

Room 4C32, Bethesda, MD 20892. 

Contact Person: John J. O’Shea, MD, PhD, 

Scientific Director, National Institute of 

Arthritis & Musculoskeletal, and Skin 

Diseases, Building 10, Room 9N228, MSC 

1820, Bethesda, MD 20892, (301) 496–2612, 

osheaj@arb.niams.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.846, Arthritis, 

Musculoskeletal and Skin Diseases Research, 

National Institutes of Health, HHS) 

Dated: January 11, 2007. 

Anna Snouffer, 

Acting Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 07–242 Filed 1–19–07; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Environmental 

Health Sciences; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The contract proposals and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the contract 

proposals, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Environmental Health Sciences Special 

Emphasis Panel, Development of an ELISA 

for Measuring Serum Levels. 

Date: February 8, 2007. 

Time: 1:30 p.m. to 3:30 p.m. 

Agenda: To review and evaluate contract 

proposals. 


rmajette on PROD1PC67 with NOTICES